2013 Biotech & Standards Conference Panelist: Leslie E. Silberstein
Director, Joint Program in Transfusion Medicine at Children’s Hospital Boston, Brigham and Women’s Hospital, and the Dana-Farber Cancer Institute Director, Center for Human Cell Therapy (CHCT), Immune Disease Institute/Programs in Cellular and Molecular Medicine, Children’s Hospital Boston; Professor of Pathology, Harvard Medical School
Dr. Silberstein received his Baccalaureate and M.D. Degrees from the University of Leiden, the Netherlands, and had post-graduate training in Hematology/Oncology and Transfusion Medicine at Tufts-New England Medical Center in Boston, MA. He then joined the staff at The University of Pennsylvania, where he worked from 1983-2000. During this time Dr. Silberstein established an academic transfusion medicine division with the Department of Pathology and Laboratory Medicine. He also served as Director of the Blood Bank and Transfusion Medicine Section, and Associate Director, Bone Marrow Transplant Program.
Dr. Silberstein was then recruited to Harvard, where he is a Professor of Pathology at Harvard Medical School and Director of the Joint Program in Transfusion Medicine at Children’s Hospital Boston, Brigham and Women’s Hospital, and the Dana-Farber Cancer Institute. The Joint Program has three interrelated components: research, clinical and educational. An increasingly prominent activity within the Joint Program is the development of cell-based therapies. In addition, Dr. Silberstein is the Director of the Center for Human Cell Therapy (CHCT) at the Immune Disease Institute/Programs in Cellular and Molecular Medicine at Children’s Hospital Boston (PICMM). The CHCT was established to provide an infrastructure to rapidly translate novel cell therapy protocols from the laboratory to the clinic. Anchored by its Translational Cell Therapy Laboratory and its Regulatory Core, the Center is designed to provide cell therapy resources for the Harvard community and its affiliated hospitals, from the technical level to the submission of Clinical Protocols and Investigational New Drug applications. He is also a Senior Investigator at the Immune Disease Institute/PICMM and Head of the Harvard Stem Cell Institute’s Translational Research Program.